Eye Diseases "Treated" With Interoperable Medical Informatics
ConditionIntravitreal Injections
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital Muenster
About this trial
The overarching goal of EyeMatics is to promote an interoperable, sustainable infrastructure for the integration and sharing of data from clinical research to improve personalized medicine in ophthalmology. To achieve this, EyeMatics bundles the expertise and preliminary work of the four consortia of the Medical Informatics Initiative (MII) and the ophthalmological centers of excellence in Germany. The perspective and concerns of patients will be strongly incorporated into the project work through close cooperation with patient representatives and the inclusion of patient feedback on quality of life and treatment success.
EyeMatics aims to improve the understanding of the therapeutic success of eye diseases that are usually treated with intravitreal surgical medication (IVOM). To this end, an exemplary analysis platform for "real" clinical data will be provided and a dashboard for data visualization and analysis will be developed as a web application. The dashboard is to be introduced at all participating hospital sites for research purposes.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
OPS code: "5-156.9 Injection of drugs into the posterior segment of the eye"
Disqualifiers
None
Trial population
Patients receiving intravitreal injections at the study centers with signed Broad Consent (Consent of the Medical Informatics Initiative Germany).
Trial design
Design model
Other
Time perspective
Other
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Medical success
changes in visual acuity during the course of treatment
Time frame
with every treatment or controll-visit within 12, 24 and 36 monthsSecondary outcomes
1
Treatment latency period:
latency period within the treatment and monitoring cycle as days between the indication/OCT examination and the implementation of IVOM treatment
Time frame
from indication to treatment begin (Depending on the treatment regimen, assessed up to 6 months)2
Treatment and monitoring frequency
Considered for the injection upload phase and for the first 12, 24 and 36 months of treatment. The number of injections is evaluated at patient level as a quality indicator and for the various treatment regimens, indications and clinical centers.
Time frame
during the procedure3
Treatment adherence
Non-adherence to treatment is defined as those patients who did not receive any control or therapy without a planned treatment/control gap of 3 months.
Time frame
during the procedure4
Treatment persistence
Treatment non-persistence is defined as the number of patients who received no further monitoring or treatment for a period of at least 6 months and did not resume treatment at the time of analysis.
Time frame
during the procedureSponsors and contacts
Click on the lead sponsor to view all of their trials.
University Hospital Muenster
Lead sponsor
University Medicine Greifswald
Collaborator
University Medical Center Mainz
Collaborator
University Hospital, Aachen
Collaborator
Klinikum Chemnitz gGmbH
Collaborator
Technische Universität Dresden
Collaborator
University of Leipzig
Collaborator
University Hospital Tuebingen
Collaborator
Deutsche Ophthalmologische Gesellschaft e.V.
Collaborator
Pro Retina Deutschland e.V.
Collaborator
Source ClinicalTrials.gov